Acceleron Pharma Inc. (XLRN)’s Financial Results Comparing With XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB)

This is a contrast between Acceleron Pharma Inc. (NASDAQ:XLRN) and XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) based on their analyst recommendations, institutional ownership, profitability, risk, dividends, earnings and valuation. The two companies are Biotechnology and they also compete with each other.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Acceleron Pharma Inc. 13.99M 153.00 118.87M -2.45 0.00
XTL Biopharmaceuticals Ltd. N/A 0.00 2.99M 0.38 5.97

Demonstrates Acceleron Pharma Inc. and XTL Biopharmaceuticals Ltd. earnings per share, top-line revenue and valuation.

Profitability

Table 2 demonstrates the net margins, return on assets and return on equity of Acceleron Pharma Inc. and XTL Biopharmaceuticals Ltd.

Net Margins Return on Equity Return on Assets
Acceleron Pharma Inc. -849.68% -36.6% -34.6%
XTL Biopharmaceuticals Ltd. 0.00% 33.2% 28.8%

Risk & Volatility

Acceleron Pharma Inc.’s 1.41 beta indicates that its volatility is 41.00% more volatile than that of Standard & Poor’s 500. In other hand, XTL Biopharmaceuticals Ltd. has beta of 1.04 which is 4.00% more volatile than Standard & Poor’s 500.

Liquidity

The Current Ratio of Acceleron Pharma Inc. is 16.2 while its Quick Ratio stands at 16.2. The Current Ratio of rival XTL Biopharmaceuticals Ltd. is 36 and its Quick Ratio is has 36. XTL Biopharmaceuticals Ltd. is better equipped to clear short and long-term obligations than Acceleron Pharma Inc.

Analyst Ratings

Acceleron Pharma Inc. and XTL Biopharmaceuticals Ltd. Ratings and Recommendations are available on the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Acceleron Pharma Inc. 0 0 2 3.00
XTL Biopharmaceuticals Ltd. 0 0 0 0.00

Acceleron Pharma Inc. has a consensus target price of $72.5, and a 78.44% upside potential.

Institutional & Insider Ownership

Acceleron Pharma Inc. and XTL Biopharmaceuticals Ltd. has shares held by institutional investors as follows: 87.4% and 11.6%. Insiders held roughly 14.2% of Acceleron Pharma Inc.’s shares. On the other hand, insiders held about 1% of XTL Biopharmaceuticals Ltd.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Acceleron Pharma Inc. 9.34% 9.06% -13.57% -13.2% 13.86% 6.18%
XTL Biopharmaceuticals Ltd. -9.64% -8.16% -0.44% 30.06% -8.16% 30.06%

For the past year Acceleron Pharma Inc. was less bullish than XTL Biopharmaceuticals Ltd.

Summary

On 8 of the 11 factors XTL Biopharmaceuticals Ltd. beats Acceleron Pharma Inc.

Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for serious and rare diseases. Its therapeutic candidates include luspatercept to treat anemia and associated complications in patients with myelodysplastic syndromes and beta-thalassemia; and sotatercept for chronic kidney diseases. The companyÂ’s therapeutic candidates also include dalantercept, a tyrosine kinase inhibitor, which is in phase II clinical trials for renal cell carcinoma; and ACE-083 that is in phase II clinical trials for facioscapulohumeral dystrophy. It has collaboration, license, and option agreement with Celgene Corporation. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and SjogrenÂ’s syndrome. The company also develops recombinant human erythropoietin for the treatment of multiple myeloma patients. XTL Biopharmaceuticals Ltd. has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was founded in 1993 and is headquartered in Raanana, Israel.